Universidade Federal de São Paulo, Escola Paulista de Medicina (UNIFESP/EPM), Departamento de Otorrinolaringologia e Cirurgia de Cabeça e Pescoço, São Paulo, SP, Brazil; Hospital Beneficência Portuguesa de São Paulo, Departamento de Cirurgia de Cabeça e Pescoço, São Paulo, SP, Brazil.
Universidade Federal de São Paulo, Escola Paulista de Medicina (UNIFESP/EPM), Departamento de Otorrinolaringologia e Cirurgia de Cabeça e Pescoço, São Paulo, SP, Brazil.
Braz J Otorhinolaryngol. 2022 Nov-Dec;88 Suppl 4(Suppl 4):S152-S162. doi: 10.1016/j.bjorl.2021.11.007. Epub 2021 Dec 10.
To investigate the prognostic factors to developing parotid and neck metastasis in locally advanced and relapsed Cutaneous Squamous Cell Carcinoma (CSCC) of the head and neck region.
Single-center retrospective cohort study enrolling consecutive patients with advanced CSCC from 2009 to 2019. Seventy-four cases were identified. Study variables demographic data, clinical skin tumor stage, neck stage, parotid stage (P stage), surgical treatment features, and parotid, regional, and distant metastases. Survival measures: Overall Survival (OS) and Disease-Specific Survival (DSS).
The study group included 72.9% men (median age, 67 years); 67.5% showed T2/T3 tumors, 90.5% comorbidities, 20.2% immunosuppressed, with median follow-up: 35.8 months. The most frequent skin primary were auricular and eyelid regions, 75% underwent primary resection with flap reconstruction. Parotid metastasis was present in 50%, 32.4% showing parotid extracapsular spread, multivariate analysis found OR = 37.6 of positive parotid metastasis evolving into positive neck metastasis, p = 0.001. Occult neck metastasis, neck metastasis, and neck extracapsular spread were observed in 13.5%, 51.3%, and 37.8%, respectively. Kaplan-Meier survival: Clinical T4 versus T1, p = 0.028, P1 stage: 30% and 5% survival at 5 and 10 years, P3 stage: 0%, p = 0.016; OS and DSS showed negative survival for the parotid metastasis group, p = 0.0283.
Our outcomes support a surgically aggressive approach for locally advanced and relapsed CSCC, with partial parotidectomy for P0, total parotidectomy for P1-3, selective I-III neck dissection for all patients and adjuvant radiochemotherapy to appropriately treat these patients with advanced CSCC of the head and neck region.
II b - Retrospective Cohort Study - Oxford Centre for Evidence-Based Medicine (OCEBM).
探讨头颈部局部晚期和复发的皮肤鳞状细胞癌(CSCC)发生腮腺和颈部转移的预后因素。
这是一项单中心回顾性队列研究,纳入了 2009 年至 2019 年期间连续就诊的局部晚期 CSCC 患者。共纳入 74 例患者。研究变量包括人口统计学数据、临床皮肤肿瘤分期、颈部分期、腮腺分期(P 分期)、手术治疗特征以及腮腺、区域和远处转移。生存评估:总生存(OS)和疾病特异性生存(DSS)。
研究组包括 72.9%的男性(中位年龄,67 岁);67.5%为 T2/T3 肿瘤,90.5%合并症,20.2%免疫抑制,中位随访时间为 35.8 个月。最常见的皮肤原发性病变为耳廓和眼睑区域,75%的患者行原发灶切除术联合皮瓣重建。50%的患者发生腮腺转移,其中 32.4%有腮腺外侵犯,多变量分析发现,腮腺阳性转移进展为颈部阳性转移的优势比(OR)为 37.6,p=0.001。隐匿性颈部转移、颈部转移和颈部外侵犯的发生率分别为 13.5%、51.3%和 37.8%。Kaplan-Meier 生存分析:临床 T4 与 T1 相比,p=0.028;P1 期:5 年和 10 年的生存率分别为 30%和 5%,P3 期:生存率为 0%,p=0.016;腮腺转移组的 OS 和 DSS 均为负性生存,p=0.0283。
我们的研究结果支持对头颈部局部晚期和复发 CSCC 进行积极的手术治疗,对于 P0 期患者行腮腺部分切除术,对于 P1-3 期患者行腮腺全切除术,所有患者行选择性 I-III 颈淋巴结清扫术,并辅助放化疗,以适当治疗头颈部晚期 CSCC 患者。
II b - 回顾性队列研究 - 牛津循证医学中心(OCEBM)。